8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Feb 25, 2026·SEC
LeMaitre Vascular, Inc.(LMAT)Earnings, Financials & Key Ratios
LMAT•NASDAQ
37.3× P/E·Price updated Jun 19, 2026
AboutLeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Show more
- Revenue$250M+13.5%
- EBITDA$78M+26.5%
- Net Income$58M+31.1%
- EPS (Diluted)2.52+30.6%
- Gross Margin71.53%+4.2%
- EBITDA Margin31.38%+11.4%
- Operating Margin27.21%+14.5%
- Net Margin23.13%+15.5%
- ROE15.8%+13.9%
LMAT Key Insights
LeMaitre Vascular, Inc. (LMAT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 22.2%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 29.8% free cash flow margin
- ✓15 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 14.0%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LMAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LMAT Price & Volume
LeMaitre Vascular, Inc. (LMAT) stock price & volume — 10-year historical chart
Loading chart...
LMAT Growth Metrics
LeMaitre Vascular, Inc. (LMAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.28%
5 Years14.05%
3 Years15.58%
TTM13.27%
Profit CAGR
10 Years22.23%
5 Years22.16%
3 Years40.91%
TTM38.17%
EPS CAGR
10 Years19.62%
5 Years19.36%
3 Years39.41%
TTM36.87%
Return on Capital
10 Years15.25%
5 Years12.25%
3 Years12.34%
Last Year12.34%
LMAT Recent Earnings
LeMaitre Vascular, Inc. (LMAT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.68+3.0%
$0.66
Rev
$67M-0.2%
$67M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.68+1.5%
$0.67
Rev
$64M+2.6%
$63M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.62+9.9%
$0.56
Rev
$61M-1.8%
$62M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.60+5.3%
$0.57
Rev
$64M+5.5%
$61M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.68vs $0.66+3.0% | $67Mvs $67M-0.2% |
| Q1 2026 | Feb 25, 2026 | $0.68vs $0.67+1.5% | $64Mvs $63M+2.6% |
| Q4 2025 | Nov 6, 2025 | $0.62vs $0.56+9.9% | $61Mvs $62M-1.8% |
| Q3 2025 | Aug 5, 2025 | $0.60vs $0.57+5.3% | $64Mvs $61M+5.5% |
Based on last 12 quarters of dataView full earnings history →
LMAT Peer Comparison
LeMaitre Vascular, Inc. (LMAT) competitors in Surgical and interventional devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 CNMD | 1B | 32.58 | 21.58 | 5.16% | 4% | 5.4% | 0.81 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 TMDX | 2.72B | 78.79 | 16.18 | 37.13% | 27.04% | 41.92% | 0.99 | |
 ELMD | 320.27M | 38.68 | 44.98 | 16.97% | 14.08% | 22.14% | 0.00 | |
 PCVX | 7.43B | 51.44 | -9.14 | -32.51% | 0.09 |
Compare LMAT vs Peers
LeMaitre Vascular, Inc. (LMAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LMAT Income Statement
LeMaitre Vascular, Inc. (LMAT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 100.87M | 105.57M | 117.23M | 129.37M | 154.42M | 161.65M | 193.48M | 219.86M | 249.6M | 256.28M |
Revenue Growth % | 13.14% | 4.66% | 11.05% | 10.35% | 19.37% | 4.68% | 19.69% | 13.63% | 13.53% | 13.27% |
Cost of Goods Sold | 30.17M | 31.63M | 37.38M | 44.75M | 53.04M | 56.76M | 66.44M | 68.96M | 71.06M | 70.77M |
COGS % of Revenue | 29.91% | 29.96% | 31.88% | 34.59% | 34.35% | 35.11% | 34.34% | 31.37% | 28.47% | - |
Gross Profit | 70.7M▲ 0% | 73.94M▲ 4.6% | 79.85M▲ 8.0% | 84.62M▲ 6.0% | 101.38M▲ 19.8% | 104.9M▲ 3.5% | 127.05M▲ 21.1% | 150.9M▲ 18.8% | 178.54M▲ 18.3% | 185.51M▲ 0% |
Gross Margin % | 70.09% | 70.04% | 68.12% | 65.41% | 65.65% | 64.89% | 65.66% | 68.63% | 71.53% | 72.39% |
Gross Profit Growth % | 12.33% | 4.59% | 8% | 5.97% | 19.81% | 3.47% | 21.12% | 18.77% | 18.32% | - |
Operating Expenses | 49.59M | 53.2M | 58.67M | 55.83M | 64.96M | 78.07M | 90.34M | 98.64M | 110.63M | 112.45M |
OpEx % of Revenue | 49.17% | 50.4% | 50.05% | 43.16% | 42.06% | 48.29% | 46.69% | 44.87% | 44.32% | - |
Selling, General & Admin | 42.96M | 45.01M | 49.39M | 46.2M | 53.16M | 61.67M | 72.89M | 83M | 96.49M | 98.35M |
SG&A % of Revenue | 42.59% | 42.63% | 42.13% | 35.71% | 34.42% | 38.15% | 37.67% | 37.75% | 38.66% | - |
Research & Development | 6.64M | 8.2M | 9.28M | 10.1M | 11.8M | 13.29M | 16.97M | 15.65M | 14.14M | 14.1M |
R&D % of Revenue | 6.58% | 7.76% | 7.91% | 7.81% | 7.64% | 8.22% | 8.77% | 7.12% | 5.66% | - |
Other Operating Expenses | 3K | 235K | 0 | -470K | 0 | 3.11M | 485K | 0 | 0 | 0 |
Operating Income | 21.1M▲ 0% | 28.21M▲ 33.7% | 21.18M▼ 24.9% | 28.79M▲ 35.9% | 36.42M▲ 26.5% | 26.83M▼ 26.3% | 36.71M▲ 36.8% | 52.26M▲ 42.3% | 67.91M▲ 30.0% | 73.06M▲ 0% |
Operating Margin % | 20.92% | 26.72% | 18.07% | 22.25% | 23.59% | 16.6% | 18.97% | 23.77% | 27.21% | 28.51% |
Operating Income Growth % | 29.18% | 33.67% | -24.91% | 35.9% | 26.53% | -26.34% | 36.84% | 42.34% | 29.96% | - |
EBITDA | 25.16M | 32.53M | 26.6M | 37.01M | 45.9M | 36.26M | 46.23M | 61.93M | 78.33M | 80.93M |
EBITDA Margin % | 24.94% | 30.82% | 22.69% | 28.61% | 29.72% | 22.43% | 23.89% | 28.17% | 31.38% | 31.58% |
EBITDA Growth % | 26.26% | 29.31% | -18.24% | 39.15% | 24.01% | -21% | 27.48% | 33.96% | 26.49% | 28.77% |
D&A (Non-Cash Add-back) | 4.06M | 4.32M | 5.42M | 8.22M | 9.47M | 9.43M | 9.52M | 9.67M | 10.42M | 7.87M |
EBIT | 21.11M | 28.45M | 21.68M | 28.67M | 36.51M | 27.49M | 39.48M | 57.08M | 80.37M | 64.84M |
Net Interest Income | 158K | 629K | 698K | -1.1M | -2.02M | 986K | 3.08M | 4.74M | 7.91M | 6.3M |
Interest Income | 179K | 631K | 698K | 207K | 197K | 986K | 3.08M | 4.95M | 13.09M | 10.19M |
Interest Expense | 21K | 2K | 0 | 1.31M | 2.22M | 0 | 0 | 205K | 5.18M | 2.59M |
Other Income/Expense | 3K | 235K | 496K | -1.43M | -2.14M | 661K | 2.76M | 4.62M | 7.27M | 7.55M |
Pretax Income | 21.11M▲ 0% | 28.44M▲ 34.8% | 21.68M▼ 23.8% | 27.36M▲ 26.2% | 34.29M▲ 25.3% | 27.49M▼ 19.8% | 39.48M▲ 43.6% | 56.88M▲ 44.1% | 75.18M▲ 32.2% | 80.61M▲ 0% |
Pretax Margin % | 20.92% | 26.94% | 18.49% | 21.15% | 22.2% | 17.01% | 20.4% | 25.87% | 30.12% | 31.46% |
Income Tax | 3.93M | 5.5M | 3.75M | 6.14M | 7.38M | 6.85M | 9.37M | 12.84M | 17.45M | 18.21M |
Effective Tax Rate % | 18.62% | 19.34% | 17.27% | 22.43% | 21.52% | 24.93% | 23.74% | 22.57% | 23.21% | 22.59% |
Net Income | 17.18M▲ 0% | 22.94M▲ 33.6% | 17.93M▼ 21.8% | 21.22M▲ 18.3% | 26.91M▲ 26.8% | 20.64M▼ 23.3% | 30.11M▲ 45.9% | 44.04M▲ 46.3% | 57.73M▲ 31.1% | 62.4M▲ 0% |
Net Margin % | 17.03% | 21.73% | 15.3% | 16.4% | 17.42% | 12.77% | 15.56% | 20.03% | 23.13% | 24.35% |
Net Income Growth % | 62.2% | 33.57% | -21.83% | 18.32% | 26.8% | -23.31% | 45.89% | 46.28% | 31.1% | 38.17% |
Net Income (Continuing) | 17.18M | 22.94M | 17.93M | 21.22M | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M | 62.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.86▲ 0% | 1.13▲ 31.4% | 0.88▼ 22.1% | 1.04▲ 18.2% | 1.25▲ 20.2% | 0.93▼ 25.6% | 1.34▲ 44.1% | 1.93▲ 44.0% | 2.52▲ 30.6% | 2.71▲ 0% |
EPS Growth % | 56.36% | 31.4% | -22.12% | 18.18% | 20.19% | -25.6% | 44.09% | 44.03% | 30.57% | 36.87% |
EPS (Basic) | 0.91 | 1.18 | 0.91 | 1.05 | 1.27 | 0.94 | 1.36 | 1.96 | 2.55 | - |
Diluted Shares Outstanding | 20.03M | 20.24M | 20.33M | 20.48M | 21.48M | 22.17M | 22.42M | 22.78M | 22.93M | 23.03M |
Basic Shares Outstanding | 18.96M | 19.43M | 19.81M | 20.25M | 21.16M | 21.98M | 22.22M | 22.45M | 22.64M | 22.8M |
Dividend Payout Ratio | 24.33% | 23.73% | 37.56% | 36.26% | 34.7% | 53.25% | 41.35% | 32.65% | 31.37% | - |
LMAT Balance Sheet
LeMaitre Vascular, Inc. (LMAT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 80.31M | 94.02M | 92.09M | 94.26M | 139.88M | 161.73M | 194.6M | 402.19M | 468.23M | 477.82M |
Cash & Short-Term Investments | 41.66M | 47.99M | 32.68M | 26.98M | 69.96M | 82.69M | 105.07M | 299.72M | 359.12M | 367.23M |
Cash Only | 19.1M | 26.32M | 11.79M | 26.76M | 13.86M | 19.13M | 24.27M | 25.61M | 28.24M | 26.85M |
Short-Term Investments | 22.56M | 21.67M | 20.89M | 214K | 56.1M | 63.56M | 80.81M | 274.11M | 330.88M | 340.38M |
Accounts Receivable | 15M | 15.72M | 16.57M | 19.55M | 19.63M | 22.04M | 25.06M | 30.06M | 33.61M | 35.77M |
Days Sales Outstanding | 54.28 | 54.36 | 51.6 | 55.16 | 46.4 | 49.77 | 47.28 | 49.91 | 49.15 | 49.25 |
Inventory | 21.05M | 25.57M | 34.63M | 39.16M | 40.65M | 45.28M | 52.33M | 55.94M | 70.42M | 70.82M |
Days Inventory Outstanding | 254.62 | 295.09 | 338.15 | 319.46 | 279.71 | 291.2 | 287.52 | 296.09 | 361.71 | 347.5 |
Other Current Assets | 2.6M | 1.82M | 4.9M | 5.95M | 5.46M | 11.72M | 12.13M | 8.98M | 5.08M | 4M |
Total Non-Current Assets | 46.01M | 59.07M | 96.25M | 158.55M | 152.92M | 148.74M | 152.18M | 149.63M | 147.46M | 151.71M |
Property, Plant & Equipment | 12.38M | 14.1M | 30.06M | 31.1M | 32.13M | 33.53M | 39.78M | 41.57M | 42.76M | 48.38M |
Fixed Asset Turnover | 8.15x | 7.49x | 3.90x | 4.16x | 4.81x | 4.82x | 4.86x | 5.29x | 5.84x | 5.84x |
Goodwill | 23.84M | 29.87M | 39.95M | 65.94M | 65.94M | 65.94M | 65.94M | 65.94M | 65.94M | 65.94M |
Intangible Assets | 8.23M | 13.69M | 24.89M | 58.91M | 52.71M | 46.53M | 41.71M | 35.82M | 33.09M | 31.67M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 178K | 194K | 259K | 909K | 568K | 991K | 3.74M | 4.87M | 4.91M | 4.97M |
Total Assets | 126.32M▲ 0% | 153.09M▲ 21.2% | 188.34M▲ 23.0% | 252.81M▲ 34.2% | 292.8M▲ 15.8% | 310.48M▲ 6.0% | 346.78M▲ 11.7% | 551.82M▲ 59.1% | 615.69M▲ 11.6% | 629.53M▲ 0% |
Asset Turnover | 0.80x | 0.69x | 0.62x | 0.51x | 0.53x | 0.52x | 0.56x | 0.40x | 0.41x | 0.42x |
Asset Growth % | 23.94% | 21.19% | 23.03% | 34.23% | 15.82% | 6.04% | 11.69% | 59.13% | 11.58% | 142.51% |
Total Current Liabilities | 13.19M | 19.76M | 20.85M | 25.14M | 21.81M | 25.33M | 29.88M | 30.61M | 36.32M | 33.37M |
Accounts Payable | 1.54M | 1.73M | 2.6M | 2.39M | 2.34M | 2.9M | 3.73M | 1.76M | 3.65M | 4.18M |
Days Payables Outstanding | 18.67 | 19.99 | 25.43 | 19.53 | 16.1 | 18.67 | 20.51 | 9.32 | 18.73 | 20.9 |
Short-Term Debt | 0 | 0 | 0 | 2.5M | 0 | 0 | 0 | 0 | 2.94M | 3.45M |
Deferred Revenue (Current) | 0 | 552K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.45M | 6.57M | 2.48M | 772K | 1.27M | 573K | 24K | 1.43M | 29.73M | 25.74M |
Current Ratio | 6.09x | 4.76x | 4.42x | 3.75x | 6.41x | 6.39x | 6.51x | 13.14x | 12.89x | 14.32x |
Quick Ratio | 4.49x | 3.46x | 2.76x | 2.19x | 4.55x | 4.60x | 4.76x | 11.31x | 10.95x | 12.20x |
Cash Conversion Cycle | 290.23 | 329.46 | 364.32 | 355.1 | 310 | 322.29 | 314.29 | 336.68 | 392.13 | 375.86 |
Total Non-Current Liabilities | 3.36M | 3.1M | 19.35M | 55.09M | 16.84M | 16.95M | 19M | 183.92M | 185.85M | 189.53M |
Long-Term Debt | 0 | 0 | 0 | 35.53M | 0 | 0 | 0 | 167.77M | 182.65M | 186.37M |
Capital Lease Obligations | 0 | 0 | 13.96M | 14.79M | 14.07M | 14.71M | 16.62M | 15.23M | 0 | 29.27M |
Deferred Tax Liabilities | 2.18M | 484K | 1.18M | 127K | 70K | 69K | 107K | 85K | 1.74M | 5.77M |
Other Non-Current Liabilities | 1.19M | 2.61M | 4.21M | 4.64M | 2.7M | 2.17M | 2.27M | 831K | 1.47M | 1.31M |
Total Liabilities | 16.55M | 22.85M | 40.2M | 80.24M | 38.65M | 42.27M | 48.88M | 214.53M | 222.17M | 222.9M |
Total Debt | 0 | 0 | 15.71M | 54.78M | 15.94M | 16.6M | 19.09M | 185.69M | 185.59M | 189.81M |
Net Debt | -19.1M | -26.32M | 3.93M | 28.01M | 2.08M | -2.54M | -5.17M | 160.07M | 157.35M | 162.96M |
Debt / Equity | - | - | 0.11x | 0.32x | 0.06x | 0.06x | 0.06x | 0.55x | 0.47x | 0.47x |
Debt / EBITDA | - | - | 0.59x | 1.48x | 0.35x | 0.46x | 0.41x | 3.00x | 2.37x | 2.35x |
Net Debt / EBITDA | -0.76x | -0.81x | 0.15x | 0.76x | 0.05x | -0.07x | -0.11x | 2.58x | 2.01x | 2.01x |
Interest Coverage | 1005.05x | 14223.00x | - | 21.88x | 16.45x | - | - | 278.44x | 15.50x | 24.99x |
Total Equity | 109.77M▲ 0% | 130.24M▲ 18.6% | 148.14M▲ 13.7% | 172.57M▲ 16.5% | 254.15M▲ 47.3% | 268.2M▲ 5.5% | 297.9M▲ 11.1% | 337.29M▲ 13.2% | 393.52M▲ 16.7% | 406.62M▲ 0% |
Equity Growth % | 25.45% | 18.64% | 13.75% | 16.49% | 47.27% | 5.53% | 11.07% | 13.22% | 16.67% | 61.62% |
Book Value per Share | 5.48 | 6.43 | 7.29 | 8.43 | 11.83 | 12.10 | 13.29 | 14.81 | 17.16 | 17.66 |
Total Shareholders' Equity | 109.77M | 130.24M | 148.14M | 172.57M | 254.15M | 268.2M | 297.9M | 337.29M | 393.52M | 406.62M |
Common Stock | 207K | 211K | 217K | 221K | 235K | 237K | 239K | 242K | 244K | 245K |
Retained Earnings | 28.33M | 45.83M | 57.03M | 70.55M | 88.13M | 97.77M | 115.43M | 145.09M | 184.72M | 194.68M |
Treasury Stock | -9.61M | -10.35M | -11.03M | -11.6M | -12.4M | -13.05M | -13.9M | -15.62M | 0 | 0 |
Accumulated OCI | -2.29M | -3.9M | -4.01M | -1.52M | -3.44M | -6.03M | -4.63M | -6.18M | -2.41M | -3.86M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LMAT Cash Flow Statement
LeMaitre Vascular, Inc. (LMAT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 22.87M | 19.51M | 14.18M | 34.8M | 35.1M | 25.38M | 36.75M | 44.12M | 81.25M | 87.31M |
Operating CF Margin % | 22.67% | 18.48% | 12.09% | 26.9% | 22.73% | 15.7% | 18.99% | 20.07% | 32.55% | - |
Operating CF Growth % | 35.35% | -14.7% | -27.31% | 145.43% | 0.87% | -27.7% | 44.81% | 20.06% | 84.14% | 332.23% |
Net Income | 17.18M | 22.94M | 17.93M | 21.22M | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M | 62.4M |
Depreciation & Amortization | 4.05M | 4.32M | 5.42M | 8.39M | 11.07M | 9.43M | 9.52M | 9.67M | 10.42M | 10.49M |
Stock-Based Compensation | 2.26M | 2.35M | 2.64M | 3.02M | 3.48M | 4.17M | 5.32M | 6.57M | 0 | 5.78M |
Deferred Taxes | 300K | -2.15M | 824K | -328K | 79K | -182K | 783K | -451K | 2.31M | 2.31M |
Other Non-Cash Items | 703K | -6.31M | 1.25M | 1.63M | 3.53M | 4.72M | 2.28M | 4.4M | 12.54M | -414K |
Working Capital Changes | -1.62M | -1.65M | -13.89M | 863K | -9.96M | -13.4M | -11.25M | -20.1M | -1.75M | 6.74M |
Change in Receivables | -1.51M | -1.28M | -1.3M | -939K | -818K | -3.53M | -3.13M | -6.42M | -2.95M | -809K |
Change in Inventory | -1.35M | -4.26M | -11.34M | -2.61M | -5.49M | -7.42M | -9.79M | -10.57M | -7.22M | -7.28M |
Change in Payables | 1.52M | 4.31M | -596K | 4.32M | -1.73M | 645K | 4.6M | -779K | 4.2M | 7.12M |
Cash from Investing | -28.96M | -7.05M | -24.1M | -52.89M | -61.08M | -10.37M | -24.71M | -200.12M | -64.94M | -73.74M |
Capital Expenditures | -6.42M | -3.05M | -3.76M | -2.98M | -4.88M | -3.23M | -7.26M | -6.96M | -6.78M | -8.18M |
CapEx % of Revenue | 6.36% | 2.89% | 3.21% | 2.31% | 3.16% | 2% | 3.75% | 3.17% | 2.72% | 3.19% |
Acquisitions | 0 | -4.88M | -21.24M | -72.63M | 0 | 0 | -899K | 0 | -1.9M | -1.9M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -22.54M | 8.28M | 0 | 2.02M | 0 | 858K | 0 | 0 | 0 | 0 |
Cash from Financing | 80K | -4.42M | -4.62M | 32.16M | 13.7M | -9.23M | -7.13M | 158.1M | -14.54M | -12.52M |
Debt Issued (Net) | 0 | 0 | 0 | 39M | -39M | 0 | 0 | 169.27M | 0 | 0 |
Equity Issued (Net) | 4.72M | 2.23M | 4.17M | 5.4M | 63.24M | 3.47M | 6.17M | 6.44M | 6.82M | 4.53M |
Dividends Paid | -4.18M | -5.45M | -6.74M | -7.7M | -9.34M | -10.99M | -12.45M | -14.38M | -18.11M | -19.3M |
Share Repurchases | -778K | -741K | -683K | -570K | 0 | 0 | 0 | 0 | 0 | 601K |
Other Financing | -463K | -1.2M | -2.06M | -4.55M | -1.2M | -1.71M | -853K | -3.23M | -3.25M | 2.26M |
Net Change in Cash | -5.19M▲ 0% | 7.22M▲ 239.1% | -14.53M▼ 301.2% | 14.98M▲ 203.1% | -12.91M▼ 186.2% | 5.28M▲ 140.9% | 5.13M▼ 2.7% | 1.34M▼ 73.9% | 2.63M▲ 96.4% | 1.51M▲ 0% |
Free Cash Flow | 16.45M▲ 0% | 16.45M▲ 0.0% | 10.42M▼ 36.7% | 31.82M▲ 205.4% | 30.22M▼ 5.0% | 22.15M▼ 26.7% | 29.49M▲ 33.1% | 37.16M▲ 26.0% | 74.47M▲ 100.4% | 79.12M▲ 0% |
FCF Margin % | 16.31% | 15.58% | 8.89% | 24.6% | 19.57% | 13.7% | 15.24% | 16.9% | 29.83% | 30.87% |
FCF Growth % | 17.06% | 0.01% | -36.68% | 205.41% | -5.02% | -26.71% | 33.13% | 26.03% | 100.39% | 92.43% |
FCF per Share | 0.82 | 0.81 | 0.51 | 1.55 | 1.41 | 1.00 | 1.31 | 1.63 | 3.25 | 3.44 |
FCF Conversion (FCF/Net Income) | 1.33x | 0.85x | 0.79x | 1.64x | 1.30x | 1.23x | 1.22x | 1.00x | 1.41x | 1.27x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 3.15M | 5.52M | 0 | 4.47M | 10.15M | 8.34M | 7.55M | 0 | 0 | 8.59M |
LMAT Key Ratios
LeMaitre Vascular, Inc. (LMAT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 17.41% | 19.12% | 12.88% | 13.23% | 12.61% | 7.9% | 10.64% | 13.87% | 15.8% | 16.19% |
Return on Invested Capital (ROIC) | 20.57% | 21.74% | 12.41% | 12.24% | 11.96% | 7.71% | 9.86% | 9.92% | 9.72% | 10.05% |
Gross Margin | 70.09% | 70.04% | 68.12% | 65.41% | 65.65% | 64.89% | 65.66% | 68.63% | 71.53% | 72.39% |
Net Margin | 17.03% | 21.73% | 15.3% | 16.4% | 17.42% | 12.77% | 15.56% | 20.03% | 23.13% | 24.35% |
Debt / Equity | - | - | 0.11x | 0.32x | 0.06x | 0.06x | 0.06x | 0.55x | 0.47x | 0.47x |
Interest Coverage | 1005.05x | 14223.00x | - | 21.88x | 16.45x | - | - | 278.44x | 15.50x | 24.99x |
FCF Conversion | 1.33x | 0.85x | 0.79x | 1.64x | 1.30x | 1.23x | 1.22x | 1.00x | 1.41x | 1.27x |
Revenue Growth | 13.14% | 4.66% | 11.05% | 10.35% | 19.37% | 4.68% | 19.69% | 13.63% | 13.53% | 13.27% |
Related:LMAT Dividend History·LMAT Revenue History·LMAT Price History·LMAT P/E History·LMAT Financial Ratios·LMAT Institutional Holders
LMAT SEC Filings & Documents
LeMaitre Vascular, Inc. (LMAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
LMAT Frequently Asked Questions
LeMaitre Vascular, Inc. (LMAT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
LeMaitre Vascular, Inc. (LMAT) reported $256.3M in revenue for fiscal year 2025. This represents a 879% increase from $26.2M in 2004.
LeMaitre Vascular, Inc. (LMAT) grew revenue by 13.5% over the past year. This is steady growth.
Yes, LeMaitre Vascular, Inc. (LMAT) is profitable, generating $62.4M in net income for fiscal year 2025 (23.1% net margin).
Dividend & Returns
Yes, LeMaitre Vascular, Inc. (LMAT) pays a dividend with a yield of 0.84%. This makes it attractive for income-focused investors.
LeMaitre Vascular, Inc. (LMAT) has a return on equity (ROE) of 15.8%. This is reasonable for most industries.
LeMaitre Vascular, Inc. (LMAT) generated $79.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.